Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022

CONCLUSION: A majority of AML clinical trials, particularly in the non-transplant setting, exclude patients with CNS involvement. Many of these trials, most notably phase 3 trials, exclude patients not only with active, but any history of CNS involvement. Further research is needed to determine optimal management of these patients in order to increase representation in large clinical trials.PMID:37751713 | DOI:10.1159/000533819

Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Dahniel Sastow Grace Van Hyfte Jonathan Feld Marina Kremyanskaya John Mascarenhas Douglas Tremblay Source Type: research